Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.66 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL48619 | 0.89 | SIGMAR1 (0.79) | SIGMAR1CYP2A6HRH3OPRM1OPRK1 | |
| SCHEMBL48269 | 0.87 | SIGMAR1 (0.80) | SIGMAR1CYP2A6HRH3OPRM1OPRK1 | |
| SCHEMBL47897 | 0.87 | SIGMAR1 (0.80) | SIGMAR1CYP2A6HRH3OPRM1OPRK1 | |
| SCHEMBL48149 | 0.87 | SIGMAR1 (0.66) | SIGMAR1CYP2A6HRH3OPRM1OPRK1 | |
| SCHEMBL48121 | 0.87 | SIGMAR1 (0.80) | SIGMAR1CYP2A6HRH3OPRM1OPRK1 | |
| SCHEMBL47835 | 0.84 | SIGMAR1 (0.76) | SIGMAR1CYP2A6HRH3OPRM1OPRK1 | |
| SCHEMBL47944 | 0.83 | SIGMAR1 (0.71) | SIGMAR1CYP2A6HRH3OPRM1OPRK1 | |
| SCHEMBL48249 | 0.83 | SIGMAR1 (0.85) | SIGMAR1CYP2A6HRH3OPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL48116 | 0.83 | SIGMAR1 (0.74) | SIGMAR1CYP2A6HRH3OPRM1OPRK1 | |
| SCHEMBL48165 | 0.83 | SIGMAR1 (0.67) | SIGMAR1HRH3OPRM1OPRK1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129535-B2 | Alkyl ether derivatives or salts thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20090111992-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111992-A1 | ALKYL ETHER DERIVATIVES OR SALTS THEREOF | AHNAK, NGF, PMP22 | SIGMAR1 1934/4885CYP2A6 3512/4885KDM4E 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.